Biotech firm Enhanced Genomics raises £13.9m led by BGF with Parkwalk
This article covers a Series A on 17 September 2025 by Enhanced Genomics, a Cambridge biotechnology company developing a 3D multi-omics platform that maps disease-associated genetic variants, founded by Peter Fraser and Stefan Schoenfelder. The company raised £13.9m in the round, led by BGF with participation from Parkwalk.
What does Enhanced Genomics do?
A multi-omics platform that maps disease-associated genetic variants in three dimensions within relevant human cell types. It converts those variant maps into drug targets to support therapeutic research and target discovery.
Why is Enhanced Genomics useful?
Problem
Researchers and drug developers cannot easily link non-coding genetic variants to the causal genes and cell types underlying disease.
Solution
Enhanced Genomics converts non-coding variation into drug targets using a genome-wide, hypothesis-free 3D multi-omics platform. It maps variants in three dimensions in relevant human cell types to identify causal biology for target discovery.
How much did Enhanced Genomics raise?
Enhanced Genomics raised £13.9m ($19m). This makes it the 14th largest funding round in September 2025 (38 recorded). And it ranks 271th of the year (501 recorded) in the Startupmag database, as of 19 September 2025.
For details on how Startupmag compiles its rankings, view our Methodology.
Who invested in Enhanced Genomics?
The key investors are listed below.
- BGF: provides growth capital across the UK and Ireland, typically backing companies that are scaling revenues and operations.
- Parkwalk: specialises in backing university spinouts and deep-tech ventures, with strong links to the Cambridge research cluster.
- Meltwind: renowned for making strategic, research-led investments in early-stage life sciences and technology across Europe.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Who founded Enhanced Genomics?
The founders of Enhanced Genomics are Peter Fraser and Stefan Schoenfelder. Dietrich Stephan is the Chairman.
We founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.
— Dietrich Stephan, Chairman of Enhanced Genomics
Where is Enhanced Genomics based?
Enhanced Genomics is based in Cambridge, UK.
What sector is Enhanced Genomics in?
Enhanced Genomics operates in the biotechnology sector. This sector uses biological science and technology to discover and develop medical treatments. In plain terms, the company looks for genetic clues to help make new medicines.
Key trends and challenges in Genomics:
Rise of 3D and multi-omics mapping
3D and multi-omics mapping, used by groups like 10x Genomics and Arima Genomics, finds cell-specific disease signals.
Growth of AI and machine learning
AI and machine learning, as used by Genomics plc, speed target prioritisation from genome-wide association studies.
Translational gap to late-stage therapies
A major challenge is translating targets into drugs, with no platform yet advancing a drug to phase III.
For a deeper look at innovation in this space, see the biotech startups in the UK.
They've invested in Enhanced Genomics
Get to know these biotech investors
Click here for a full list of 7,526+ startup investors in the UK